Changes in QoL and Symptoms in Patients With Polycythemia Vera Receiving Ruxo in a Routine Clinical Practice (QoL-PV-R)
Changes in Quality of Life (QoL) and Symptoms in Patients With Polycythemia Vera (PV) Receiving Ruxolitinib (Ruxo) in a Routine Clinical Practice
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Tatiana Nikitina, MD, PhD
- Phone Number: 89627101712
- Email: tnikitina_74@mail.ru
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients who have confirmed diagnosis of PV
- Patients whose age - 18 years and older
- Patients who signed informed consent
- Patients who able to fill out questionnaires
Exclusion Criteria:
- Patients enrolled in clinical trials
- Patients with contraindications to Ruxo in accordance with instruction for use
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in QoL as per SF-36 questionnaire domains at 3 and 9 months of Ruxo treatment
Time Frame: Baseline, 3 and 9 months of Ruxo treatment
|
The difference in QoL means of SF-36 domains at 3 and 9 months as compared to their Baseline will be analyzed
|
Baseline, 3 and 9 months of Ruxo treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in MPN10 Total score over time
Time Frame: Baseline, 1, 3, 6, 9 and 12 months of Ruxo treatment
|
The difference in MPN10 Total Symptom Score means by MPN10 at different time-points of Ruxo treatment as compared to their Baseline will be analyzed.
Also the percentage of patients with the lowest symptom burden, corresponding to MPN10 Total scores of 0 - 7 (quartile 1), at different treatment time-points (Baseline, 1, 3, 6, 9 and 12 months) will be calculated
|
Baseline, 1, 3, 6, 9 and 12 months of Ruxo treatment
|
|
Change From Baseline in severity of each symptom by MPN10 over time
Time Frame: Baseline, 1, 3, 6, 9 and 12 months of Ruxo treatment
|
The difference in MPN10 symptom score means at different time-points of Ruxo treatment as compared to their Baseline will be analyzed
|
Baseline, 1, 3, 6, 9 and 12 months of Ruxo treatment
|
|
Percentage of patients achieving a ≥ 50% improvement from Baseline in MPN10 Total Symptom Score over time
Time Frame: 1, 3, 6, 9 and 12 months of Ruxo treatment
|
The number of patients with MPN10 Total Symptom Score decrease ≥ 50% at 1, 3, 6, 9 and 12 months of Ruxo treatment as compared to its' Baseline will be calculated
|
1, 3, 6, 9 and 12 months of Ruxo treatment
|
|
Change From Baseline in QoL as per SF-36 questionnaire domains over 12 months of Ruxo treatment
Time Frame: Baseline, 1, 3, 6, 9 and 12 months of Ruxo treatment
|
The difference in QoL means of SF-36 domains at different time-points of Ruxo treatment as compared to their Baseline will be analyzed
|
Baseline, 1, 3, 6, 9 and 12 months of Ruxo treatment
|
|
The percentage of patients who achieved overall clinicohematologic response at 9 months of treatment with Ruxo
Time Frame: 9 months
|
Overall clinicohematologic response will be defined as any participant who achieved a complete or partial clinicohematologic response per the National criteria for response in polycythemia vera (2021) and European LeukNet recommendations (2013).
A complete response (CR) will be defined as: hematocrit control (<45%) with the absence of phlebotomy eligibility ≥12 weeks, spleen volume reduction at least 35% from baseline, platelet count less than or equal to 400 x 109/L, and white blood cell count less than or equal to 10 x 109/L, and symptom regress during ≥12 weeks as well as histological remission.
A Partial Response (PR) will be defined as all the above criteria excluding histological remission
|
9 months
|
|
The Percentage of patients who achieved hematocrit (Hct) control at 9 months of treatment with Ruxo
Time Frame: 9 months
|
Hematocrit control is Ht <45% with the absence of phlebotomy eligibility beginning at 3 months visit and continuing through 9 months
|
9 months
|
|
The percentage of patients with positive changes of wellbeing during Ruxo treatment
Time Frame: 1, 3, 6, 9 and 12 months of Ruxo treatment
|
The number of patients who reported improvement as per Patient Global Impression of Changes scale at different time-points of treatment will be analyzed
|
1, 3, 6, 9 and 12 months of Ruxo treatment
|
|
The percentage of patients satisfied/dissatisfied with Ruxo treatment over time
Time Frame: 1, 3, 6, 9 and 12 months of Ruxo treatment
|
The number of patients satisfied/dissatisfied with treatment according to Patient' Treatment Satisfaction Checklist at different time-points of treatment will be analyzed
|
1, 3, 6, 9 and 12 months of Ruxo treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CINC424BRU04T
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.